SUTRO BIOPHARMA, INC. (STRO) Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Sutro Biopharma, Inc. NASDAQ:STRO Healthcare · Biotechnology
AH Close $9.33 +0.00% vs close
AH Close $9.33 +0.00% vs close
All Press Release SEC Filings News
Press Release
Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors
Sutro Biopharma dosed the first patient in a Phase 1 trial of STRO-006, its ITGB6-targeting exatecan ADC with a drug-to-antibody ratio of 8, in advanced solid tumors.
STRO-006 is the company's second wholly-owned ADC to enter the clinic in under a year; the open-label multicenter dose-escalation trial starts at 1.5 mg/kg, supported by tolerability in non-human primates at doses up to 30 mg/kg.
Initial clinical data are not expected until the second half of 2027, so this milestone is pipeline execution rather than a near-term catalyst.
• 4d ago AI analysis › Press Release
Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference
Sutro Biopharma announced its participation in the 17th Annual World ADC Conference in San Diego, October 12-15, 2026.
The company will present early clinical safety and pharmacokinetic data on STRO-004, plus preclinical insights on STRO-006 and its first wholly-owned dual-payload ADC, STRO-227.
No new clinical results or financial disclosures were included; this is a standard scientific-conference visibility announcement.
• 13d ago AI analysis › Press Release
Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development
Sutro Biopharma appointed Lucas Donigian as Senior Vice President, Business Development, effective September 28, 2026.
Donigian brings 20+ years of biotech BD experience, most recently leading Zymeworks' licensing of zanidatamab to Jazz Pharmaceuticals, with prior roles at NanoString and OncoMed.
CEO Jane Chung signaled Sutro will pursue strategic collaborations around its ADC platform alongside pipeline progress on STRO-004, STRO-006, and STRO-227.
In connection with the hire, Sutro granted inducement stock options for 25,000 shares and 1,750 RSUs under Nasdaq Listing Rule 5635(c)(4).
• 26d ago AI analysis › News
Why is Sutro Biopharma Stock Falling On Wednesday?
benzinga.com • 2mo ago Press Release ● Major ⚠ 2
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
Sutro reported encouraging early Phase 1 data for STRO-004, showing confirmed partial responses in pancreatic, head and neck, and non-small cell lung cancer patients at dose levels of 3-4 mg/kg.
The company maintains a strong balance sheet with $164.3 million in cash, which is expected to fund operations into at least the second quarter of 2028, while progress continues on STRO-006 and the STRO-227 IND submission.
Financial results for the quarter showed revenue of $9.8 million, down from $63.7 million in the prior year, driven primarily by collaboration timing, with total operating expenses decreasing to $39.5 million.
• 2mo ago AI analysis › SEC Filing
STRO: 8-K · proxy statement
Sutro Biopharma, Inc. (STRO) reported the results of its 2026 Annual Meeting of Stockholders held on June 5, 2026. The stockholders elected Jane Chung, Connie Matsui, and James Panek as Class II directors, each serving a three-year term expiring in 2029.
The meeting also saw the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 13,893,289 shares voting in favor. Additionally, shareholders approved the compensation of named executive officers on a non-binding advisory basis, with 11,329,946 shares voting in favor.
SEC 8-K • 4mo ago SEC Filing ⚠ 5
STRO: 10-Q · periodic report
Sutro Biopharma reported a net loss of $38.5 million for the first quarter of 2026, driven by $36.6 million in R&D expenses and $7.6 million in G&A costs, though total operating expenses declined 49% year-over-year due to significant restructuring. The company generated $14.5 million in revenue, primarily from collaboration agreements with Astellas, including a $10 million milestone payment for the initiation of a Phase 1 trial.
The filing discloses a 1-for-10 reverse stock split that became effective in December 2025 to maintain Nasdaq listing compliance, and a subsequent $110 million equity offering in February 2026 at $13.98 per share. As of March 31, 2026, Sutro held $202.6 million in cash and marketable securities, which management believes is sufficient to fund operations for at least the next twelve months.
Strategically, Sutro has deprioritized its late-stage candidate luveltamab tazevibulin and exited its internal manufacturing facility, refocusing resources on its next-generation ADC pipeline including STRO-004, STRO-006, and STRO-227. The company continues to incur significant non-cash interest expense of $9.5 million related to the deferred royalty obligation from its 2023 sale of future royalties to Blackstone.
SEC 10-Q • 5mo ago AI analysis › Press Release ● Major ⚠ 2
Sutro Biopharma Reports First Quarter 2026 Financial Results and Business Highlights
Sutro Biopharma reported Q1 2026 revenue of $14.5 million and a net loss of $38.5 million, significantly improved from a $76.0 million net loss in Q1 2025.
The improvement was driven by a 49% year-over-year reduction in operating expenses, largely due to the closure of the luvelta program and associated restructuring costs, alongside disciplined R&D execution.
The company completed a $110 million public offering at $13.98 per share, bringing its cash position to $202.6 million and extending its runway into at least the second quarter of 2028.
Clinically, the lead asset STRO-004 is on track for initial safety and activity data readouts in mid-2026, while the partnered dual-payload iADC with Astellas has entered the clinic.
• 5mo ago AI analysis › Press Release
Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
globenewswire.com • 6mo ago News
Sutro Biopharma (NASDAQ:STRO) Trading 10.4% Higher on Analyst Upgrade
defenseworld.net • 6mo ago 
